Wolinsky, JS; Narayana, PA; O'Connor, P; Coyle, PK; Ford, C; Johnson, K; ... Stark, Y; + view all Wolinsky, JS; Narayana, PA; O'Connor, P; Coyle, PK; Ford, C; Johnson, K; Miller, A; Pardo, L; Kadosh, S; Ladkani, D; Kastrukoff, L; Duquette, P; Freedman, M; Debouverie, M; Lubetski, C; Edan, G; Roullet, E; Confavreux, C; Thompson, A; Blumhardt, L; Hawkins, S; Scott, T; Wynn, D; Cooper, J; Thurston, S; Elias, S; Markowitz, C; Mattson, D; Noseworthy, J; Shuster, E; Carter, J; Lublin, F; Stuart, W; Kaufman, M; Birnbaum, G; Rammohan, K; Whitham, R; Mihai, C; Greenberg, S; Smith, C; Agius, M; Van Den Noort, S; Myers, L; Nelson, J; Goodin, D; Arnason, B; Bashir, K; Lynch, S; Coyle, P; Kamin, S; Sheremata, W; Mitchell, G; Goodman, A; Kachuck, N; Dunne, P; Lindsey, JW; Frohman, E; Bowen, J; Brooks, B; Rose, J; Moses, H; Jeffrey, D; Cross, A; Lisak, R; Vollmer, T; Antel, J; Cutter, G; Metz, L; McFarland, H; Reingold, S; Lublin, FD; Vainrub, I; Lambert, L; Zhong, F; Rasmituth, J; Momin, S; Kreitman, R; Shifroni, G; Pinchasi, I; Stark, Y; - view fewer (2007) Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology , 61 (1) 14 - 24. 10.1002/ana.21079.
Full text not available from this repository.
Objective: To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. Methods: A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3-year, double-blind trial. The primary end point was an intention-to-treat analysis of time to 1- (entry expanded disability status scale, 3.0-5.0) or 0.5-point expanded disability status scale change (entry expanded disability status scale, 5.5-6.5) sustained for 3 months. The trial was stopped after an interim analysis by an independent data safety monitoring board indicated no discernible treatment effect on the primary outcome. Intention-to-treat analyses of disability and magnetic resonance imaging end points were performed. Results: There was a nonsignificant delay in time to sustained accumulated disability in GA- versus PBO-treated patients (hazard ratio, 0.87 [95% confidence interval, 0.71-1.07]; p = 0.1753), with significant decreases in enhancing lesions in year 1 and smaller increases in T2 lesion volumes in years 2 and 3 versus PBO. Post hoc analysis showed that survival curves for GA-treated male patients diverged early from PBO-treated male subjects (hazard ratio, 0.71 [95% confidence interval, 0.53-0.95]; p = 0.0193). Interpretation: The trial failed to demonstrate a treatment effect of GA on primary progressive multiple sclerosis. Both the unanticipated low event rate and premature discontinuation of study medication decreased the power to detect a treatment effect. Post hoc analysis suggests GA may have slowed clinical progression in male patients who showed more rapid progression when untreated. © 2007 American Neurological Association Published by Wiley-Liss, Inc.
|Title:||Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Brain Sciences|
Archive Staff Only: edit this record